Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00709397 · ClinicalTrials.gov registry record
HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy
A clinical trial, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- 3
- Enrollment target
NCT00709397 is a clinical trial that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 3 participants.
The verdict
NCT00709397 was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
This study is designed to determine how quickly HIV-1 is cleared from the blood in treatment-experienced patients beginning a salvage therapy regimen that includes the integrase inhibitor raltegravir. The hypothesis is that HIV-1 is cleared as rapidly in these patients as in treatment-naive patients starting a raltegravir-based regimen.
Interventions
- OTHER blood drawing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00709397
The ClinicalTrials.gov registry entry for NCT00709397 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which blood drawing is the first listed.
NCT00709397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00709397 about?
NCT00709397 is a clinical study titled "HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy". This study is designed to determine how quickly HIV-1 is cleared from the blood in treatment-experienced patients beginning a salvage therapy regimen that includes the integrase inhibitor raltegravir. The hypothesis is that HIV-1 is cleared as rapidly in these patients as in treatment-naive patients...
What is the current status of trial NCT00709397?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2008-06. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00709397?
The interventions under investigation include: blood drawing (OTHER).
Who is sponsoring clinical trial NCT00709397?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.